Semax: distinguishing it from N-acetyl Semax on a certificate

What Semax is

Semax is a seven-residue synthetic peptide built from the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension. The literature describes it as lacking the hormonal activity of the parent ACTH molecule, which is the point of the modification.

Published research is largely preclinical neuroscience — rodent models examining cerebral ischemia, neurotrophin expression and neuroinflammation, with more recent work on copper binding and amyloid interactions. Human evidence exists but is limited and concentrated in a regionally specific clinical literature.

There is no FDA- or EMA-approved Semax product. Material supplied under this name is a research compound for laboratory use only.

The modified analogue problem

The most common identity issue with Semax is not adulteration but substitution with a close relative. N-acetyl Semax amidate is a distinct compound, separately indexed in chemical databases, sitting roughly 41 Da heavier than Semax as a result of its acetyl and amide modifications.

Both are legitimate compounds. The question a certificate has to answer is which one is in the vial — and a purity percentage cannot, because each could be individually pure. Only identity determination by mass or sequence resolves it.

A 41 Da separation is comfortably within the resolving power of ordinary mass spectrometry, so this is not a hard analytical problem. It is simply one that goes unanswered whenever a certificate reports purity alone.

The reason the modified analogue exists at all is instructive. Terminal modifications of this kind — acetylation at the N-terminus, amidation at the C-terminus — are a standard medicinal-chemistry approach to slowing enzymatic degradation, since the unmodified termini are where peptidases tend to begin. So the acetylated amidated form is not a corruption of Semax; it is a deliberate derivative with different properties. That is precisely why the distinction has to be made analytically rather than assumed from a product name: two legitimate compounds, closely related, sold under confusingly similar labels.

Reading the analysis

Confirm the reported mass is consistent with Semax near 814 Da rather than the acetylated amidated analogue. Semax contains a methionine residue, so it is one of the sulfur-containing peptides in common supply — a detail that can corroborate a formula on a certificate.

That methionine also means oxidation is a plausible degradation route, appearing as species 16 Da heavier. A certificate reporting related substances against a specification is describing this properly; one reporting a single number is not.

Beyond identity, apply the standard reading: purity by RP-HPLC with method and wavelength stated, net peptide content where reported, contamination controls present, lot matching the vial, and the document verifiable with the issuing laboratory.

One contextual note belongs on any honest page about this compound. A meaningful share of the human clinical literature on Semax originates from a single national research tradition and is not widely replicated elsewhere, which is a different evidential situation from a compound with multi-centre international trials behind it. That is an observation about the evidence base, not a judgement of the individual studies. It matters here because it explains why a compound can have decades of published work and still sit outside approved use anywhere — and why the analytical question of what is in the vial is the part a supplier can actually answer.

Questions researchers ask

At a glance

Class

Synthetic heptapeptide — ACTH(4-7) with C-terminal Pro-Gly-Pro

Expected mass

≈ 814 Da

Confused with

N-acetyl Semax amidate (≈ 41 Da heavier, separately indexed)

Degradation signature

+16 Da oxidation (contains methionine)

Status

Research use only — no FDA- or EMA-approved product

How our Semax lots test

Applying the same standard described above to our own material. Each certificate below opens on the issuing laboratory's portal— not a PDF hosted here — so you are reading the lab's record, not ours.

Sources

Written from primary literature and published standards — never from other suppliers' marketing copy.

• PubChem CID 9811102 — Semax, formula, mass, CAS and sequence ↗
• Dolotov OV et al., J Neurochem 2006 — Semax binds specifically and increases BDNF in rat basal forebrain ↗
• Medvedeva EV et al., Int J Mol Sci 2021 — protective effect of the ACTH(4-7)PGP peptide in a rat ischemia model (PMC) ↗
• USP General Chapter ⟨1503⟩ Quality Attributes of Synthetic Peptide Drug Substances ↗

Related notes